CJC-1295 + Ipamorelin 5+5mg

What is CJC-1295 + Ipamorelin ?

CJC-1295 + Ipamorelin 5+5mg is one vial holding 5mg of CJC-1295 without DAC and 5mg of ipamorelin, lyophilised together. Also written CJC1295/ipamorelin, it pairs a GHRH analogue with a selective ghrelin-receptor agonist.

CJC-1295 without DAC, or modified GRF (1-29), is a 29 amino acid GHRH analogue with four substitutions: D-Ala2, Gln8, Ala15 and Leu27. It acts at the GHRH receptor. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH₂, a selective agonist at the ghrelin receptor, GHS-R1a. Both receptors sit on the pituitary somatotroph.

Equal mass is not equal moles. At 3367.9 and 711.85 g/mol, the vial holds about 1.5 µmol of CJC-1295 and 7.0 µmol of ipamorelin, roughly 1 to 4.7.

CJC-1295 + Ipamorelin Research Applications

Typical preclinical uses are dual-receptor somatotroph stimulation and pulsatile GH release studies with both inputs applied together. The fixed ratio removes one source of preparation error across a replicate series.

CJC-1295 + Ipamorelin vs the Components Alone

The blend gives both peptides from one vial, one reconstitution and one certificate, at a fixed 1:1 mass ratio. That suits designs that apply both inputs together. The ratio cannot change once the powder is dissolved. A single-agent control arm, independent concentrations or attribution to one receptor need the separate CJC-1295 and ipamorelin vials. No controlled study of this specific blend has been published, so the evidence comes from each peptide's own literature.

Research Overview

This is a single vial containing two distinct growth hormone secretagogues, CJC-1295 without DAC and Ipamorelin, supplied pre-blended at 5mg of each. The two act on separate receptors, which is the entire reason they are studied together rather than as alternatives to one another.

CJC-1295 without DAC is more precisely described as tetrasubstituted GRF(1-29), a 29-amino-acid fragment of growth hormone releasing hormone carrying four substitutions (D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27). The substitution at position 2 is the functionally important one: it blocks cleavage by dipeptidyl peptidase-4, the protease that degrades native GRF within minutes. It binds the GHRH receptor on the pituitary somatotroph and signals through the cAMP/PKA pathway. Because it lacks the drug affinity complex, it does not covalently bind serum albumin and its action remains short, which is precisely what makes it useful for studying pulse shape rather than sustained elevation.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts at a completely different target, the ghrelin receptor GHS-R1a. Raun and colleagues (Eur J Endocrinol, 1998) characterised it as the first growth hormone releasing peptide with selectivity approaching that of GHRH itself, reporting growth hormone release without the accompanying ACTH and cortisol elevation seen with earlier compounds in the class such as GHRP-6 and hexarelin. That selectivity is the single most cited property of the molecule.

Pairing a GHRH analogue with a GHS-R1a agonist is a long-standing design in secretagogue research, following the work of Bowers and colleagues showing that the two classes produce a greater combined response than either alone. The usual mechanistic explanation is that the GHRH arm drives somatotroph cAMP signalling while the GHRP arm additionally attenuates somatostatin tone, so the two are acting on different limbs of the same axis rather than competing for one receptor.

Storage and Reconstitution

Store the sealed vial at -20°C, away from light and moisture, for up to 24 months. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks, or freeze single-use aliquots at -20°C. Both peptides share one reconstitution date, so aliquot at the start.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Treat the vial as one 10mg preparation, with the fill volume set by the concentration your design needs. Let the vial and the bacteriostatic water reach room temperature and swab both stoppers with alcohol. Add the water slowly down the inside wall of the vial and swirl gently until dissolved. Do not shake or vortex. The solution should be clear and colourless.

• Both components are in the same vial and go into solution together, so the blend cannot be separated after reconstitution. Study designs needing the two compounds at independent concentrations should use the separate CJC-1295 and Ipamorelin vials instead.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (Teichman et al., J Clin Endocrinol Metab, 2006; DAC form)
• Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol, 1998)
• GH-releasing peptide and GHRH in normal men (Bowers et al., J Clin Endocrinol Metab, 1990)
• Dipeptidylpeptidase IV and trypsin-like degradation of GHRH in plasma (Frohman et al., J Clin Invest, 1989)

Published research on CJC-1295 + Ipamorelin is indexed on PubMed. See our full UK buyer's guide for Ipamorelin, UK buyer's guide for CJC-1295 and UK buyer's guide for CJC-1295 Ipamorelin.